日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

RET 改变实体瘤中选择性 RET 抑制剂耐药的基因组机制图谱:RETregistry 全球联盟分析

Waliany, Sarah; Cooper, Alissa J; Liu, Stephen V; Gautschi, Oliver; Rotow, Julia K; Smith, Katherine Emilie Rhoades; Weber, Urs M; Lee, Dae Ho; Loong, Herbert H F; Patel, Jyoti D; Pennell, Nathan A; Nagasaka, Misako; Patel, Shetal A; Tan, Daniel S W; Solomon, Benjamin J; Kim, Tae Min; Pall, Georg; Riess, Jonathan W; Sun, Lova; Früh, Martin; Uy, Natalie F; Gadgeel, Shirish; Feng, Jamie; Do, Andrew; Falcon, Christina; Leighl, Natasha B; Baik, Christina S; Lai, Gillianne G Y; Ou, S Ignatius; Cheung, Kingsley S Y; Patil, Tejas; Mansfield, Aaron S; Weiler, Daniela; Yeap, Beow Y; Wirth, Lori J; Gainor, Justin F; Drilon, Alexander; Lin, Jessica J

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors

TAPISTRY:阿特珠单抗治疗肿瘤突变负荷高肿瘤患者的II期研究

Thomas, David M; Kim, Jeong Eun; Barlesi, Fabrice; Martens, Uwe M; Krzakowski, Maciej; Dziadziuszko, Rafal; Jeong, Jae Ho; Daniele, Gennaro; Wilson, Timothy R; Wu, Felice; Simmons, Brian P; Patel, Sid; Sbirnac, Maria; Kaul, Monika; Gadgeel, Shirish M

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

在一项针对携带 KRAS G12C 突变的晚期实体瘤患者的 II 期临床试验中,KRAS G12C 抑制剂 Garsorasib 联合或不联合 EGFR 抗体西妥昔单抗,用于治疗结直肠癌患者。

Ruan, Dan-Yun; Wu, Hao-Xiang; Xu, Ye; Munster, Pamela N; Deng, Yanhong; Richardson, Gary; Yan, Dong; Lee, Myung-Ah; Lee, Keun-Wook; Pan, Hongming; Hager, Steven; Li, Xingya; Wei, Shaozhong; Hou, Xinfang; Underhill, Craig; Millward, Michael; Nordman, Ina; Zhang, Jingdong; Shan, Jianzhen; Han, Guohong; Grewal, Jaspreet; Gadgeel, Shirish M; Sanborn, Rachel E; Huh, Seok Jae; Hu, Xiaohua; Zhang, Yihong; Xiang, Ziyong; Luo, Laisheng; Xie, Xiaoxi; Shi, Zhe; Wang, Yaolin; Zhang, Ling; Wang, Feng; Xu, Rui-Hua

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

tarlatamab治疗第1周期采用6-8小时门诊监测与48小时住院监测的安全性比较:DeLLphi-300 1期子研究

Chiang, A C; Olmedo Garcia, M E; Carlisle, J W; Dowlati, A; Reguart, N; Felip, E; Jost, P J; Steeghs, N; Stec, R; Gadgeel, S M; Loong, H H; Jiang, W; Hamidi, A; Parkes, A; Paz-Ares, L

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

CRESTONE:一项评估HER3单克隆抗体Seribantumab治疗伴有Neuregulin-1 (NRG1)融合的实体瘤的疗效和安全性的II期研究

Patil, Tejas; Lin, Jessica J; Cheema, Parneet K; Carrizosa, Daniel R; Burkard, Mark E; Elamin, Yasir Y; Desai, Jayesh; Patel, Jyoti D; Nagasaka, Misako; Reckamp, Karen L; Waqar, Saiama N; Bauman, Jessica R; Schram, Alison M; Gadgeel, Shirish M; Ma, Patrick C; Konduri, Kartik; Nguyen, Danny; Misleh, Jamal; Bleeker, Jonathan; Weiss, Matthias; Thavaneswaran, Subotheni; Haura, Eric B; Deegan, Maegan; Kaufman, Jonathan; Srivastava, Jaya; Jansen, Valerie M; Liu, Stephen V

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer

对于既往接受过治疗的小细胞肺癌患者,使用靶向δ样配体3的双特异性T细胞衔接器免疫疗法tarlatamab治疗时,不良事件的实用管理

Sands, Jacob M; Champiat, Stéphane; Hummel, Horst-Dieter; Paulson, Kelly G; Borghaei, Hossein; Alvarez, Jean Bustamante; Carbone, David P; Carlisle, Jennifer W; Choudhury, Noura J; Clarke, Jeffrey M; Gadgeel, Shirish M; Izumi, Hiroki; Navarro, Alejandro; Lau, Sally C M; Lammers, Philip E; Huang, Shuang; Hamidi, Ali; Mukherjee, Sujoy; Owonikoko, Taofeek K

SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy.

SMURF2 促进 GAP17 亚型 1 膜置换,从而促进突变 p53-KRAS 致癌协同作用

Ray Paramita, Shukla Shirish, Zhang Yaqing, Donahue Katelyn L, Nancarrow Derek J, Kasturirangan Srimathi, Shankar Sunita, Cuneo Kyle, Thomas Dafydd, Gadgeel Shirish M, Lawrence Theodore S, Pasca di Magliano Marina, Ray Dipankar

Proceedings of the 1st biannual bridging the gaps in lung cancer conference

第一届两年一度的“弥合肺癌治疗差距”会议论文集

Florez, Narjust; Patel, Sandip P; Wakelee, Heather; Bazhenova, Lyudmila; Massarelli, Erminia; Salgia, Ravi; Stiles, Brendon; Peters, Solange; Malhotra, Jyoti; Gadgeel, Shirish M; Nieva, Jorge J; Afkhami, Michelle; Hirsch, Fred R; Gubens, Matthew; Cascone, Tina; Levy, Benjamin; Sabari, Joshua; Husain, Hatim; Ma, Patrick C; Backhus, Leah M; Iyengar, Puneeth; Lee, Percy; Miller, Russell; Sands, Jacob; Kim, Edward

Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies

接受标准治疗的转移性ALK融合阳性实体瘤患者的真实世界特征和生存结果

Gadgeel, Shirish M; Fajardo, Otto; Barlesi, Fabrice; Eun Kim, Jeong; Kurzrock, Razelle; Thomas, David M; Jagtiani, Ritika; Noe, Johannes; Schwemmers, Sven; Nikolaidis, Christos

Is Shorter Better in Oncology Patients, Too? A Retrospective Cohort Study of Short- Versus Long-Course Antibiotic Therapy for Uncomplicated Infections in Solid Tumor Patients Receiving Care in Ambulatory Oncology Clinics

肿瘤患者也适用疗程短的疗效吗?一项回顾性队列研究比较了门诊肿瘤诊所接受治疗的实体瘤患者非复杂性感染的短期与长期抗生素治疗效果。

Arena, Christen J; El-Tatari, Beisan; Lovric, Kristen; Greenlee, Sage B; Kenney, Rachel M; Gadgeel, Shirish M; Patterson, Katelyn; Shallal, Anita B; Alangaden, George J; Davis, Susan L; Veve, Michael P